Zacks: Brokerages Expect NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.31 Per Share

Share on StockTwits

Brokerages expect that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings of ($0.31) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for NewLink Genetics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.32). NewLink Genetics reported earnings of ($0.49) per share during the same quarter last year, which indicates a positive year over year growth rate of 36.7%. The company is scheduled to issue its next quarterly earnings report after the market closes on Wednesday, May 8th.

According to Zacks, analysts expect that NewLink Genetics will report full-year earnings of ($0.80) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($0.12). For the next year, analysts expect that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.17) to ($1.14). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover NewLink Genetics.

NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.06. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.38 million. NewLink Genetics had a negative return on equity of 42.86% and a negative net margin of 429.65%.

NLNK has been the subject of several research reports. Bank of America downgraded NewLink Genetics from a “neutral” rating to an “underperform” rating in a research note on Thursday, January 3rd. Robert W. Baird reduced their target price on NewLink Genetics from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, February 28th. ValuEngine downgraded NewLink Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $4.40.

Shares of NLNK traded up $0.07 during trading hours on Friday, hitting $1.80. The stock had a trading volume of 2,419 shares, compared to its average volume of 467,178. The company has a market cap of $64.12 million, a PE ratio of -1.24 and a beta of 1.79. NewLink Genetics has a 1-year low of $1.28 and a 1-year high of $5.61.

A number of hedge funds have recently added to or reduced their stakes in NLNK. Vanguard Group Inc raised its holdings in NewLink Genetics by 9.3% during the 3rd quarter. Vanguard Group Inc now owns 1,614,773 shares of the biotechnology company’s stock valued at $3,860,000 after acquiring an additional 136,947 shares during the period. Vanguard Group Inc. grew its position in shares of NewLink Genetics by 9.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,614,773 shares of the biotechnology company’s stock valued at $3,860,000 after purchasing an additional 136,947 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of NewLink Genetics by 229.8% during the 3rd quarter. Renaissance Technologies LLC now owns 1,335,981 shares of the biotechnology company’s stock valued at $3,193,000 after purchasing an additional 930,881 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of NewLink Genetics by 148.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,156,871 shares of the biotechnology company’s stock valued at $2,765,000 after purchasing an additional 691,651 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of NewLink Genetics by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 497,756 shares of the biotechnology company’s stock valued at $756,000 after purchasing an additional 14,944 shares in the last quarter. Institutional investors and hedge funds own 34.54% of the company’s stock.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Article: Bond

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.